Bupivacaine
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Bupivacaine |
| DrugBank ID | DB00297 |
| Brand Names (EU) | Exparel liposomal |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.49% |
Approved Indication (EMA)
Exparel liposomal is indicated: in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain. in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | dermatitis | 99.49% | DL |
| 2 | acrodermatitis chronica atrophicans | 99.23% | DL |
| 3 | neonatal dermatomyositis | 99.15% | DL |
| 4 | secondary interstitial lung disease specific to childhood associated with a connective tissue disease | 99.11% | DL |
| 5 | amyopathic dermatomyositis | 99.03% | DL |
| 6 | acne keloid | 98.98% | DL |
| 7 | hydroa vacciniforme, familial | 98.96% | DL |
| 8 | uterine polyp | 98.90% | DL |
| 9 | epulis | 98.90% | DL |
| 10 | polyp of vocal cord | 98.87% | DL |
| 11 | polyp of middle ear | 98.86% | DL |
| 12 | fibroepithelial polyp | 98.83% | DL |
| 13 | polyp of ureter | 98.82% | DL |
| 14 | polyp of frontal sinus | 98.82% | DL |
| 15 | neoplastic polyp | 98.81% | DL |
| 16 | polyp of vulva | 98.79% | DL |
| 17 | polyp of external auditory canal | 98.79% | DL |
| 18 | papillary conjunctivitis | 96.83% | DL |
| 19 | bronchitis | 95.71% | DL |
| 20 | nasal cavity polyp | 93.30% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.